Editas Medicine, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EDIT Nasdaq 2836 www.editasmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Editas Medicine, Inc.

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel - Dec 10th, 2024 4:13 pm
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting - Dec 9th, 2024 5:00 pm
Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? - Dec 4th, 2024 4:30 pm
Editas Medicine downgraded to Underperform from Buy at BofA - Nov 26th, 2024 11:50 am
Editas Medicine to Participate in Upcoming Investor Conferences - Nov 6th, 2024 2:00 pm
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% - Nov 6th, 2024 12:02 pm
Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - Nov 5th, 2024 6:59 pm
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - Nov 5th, 2024 4:01 pm
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Nov 5th, 2024 2:00 pm
Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Nov 5th, 2024 10:43 am
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - Nov 4th, 2024 1:40 pm
Editas: Q3 Earnings Snapshot - Nov 4th, 2024 12:36 pm
Editas Medicine Announces Third Quarter 2024 Results and Business Updates - Nov 4th, 2024 12:30 pm
Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Oct 31st, 2024 7:55 am
Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for - Oct 28th, 2024 2:01 pm
Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline - Oct 25th, 2024 2:00 pm
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More - Oct 24th, 2024 3:49 pm
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down - Oct 23rd, 2024 3:29 pm
Editas and Genevant team up to develop gene editing therapies - Oct 22nd, 2024 4:13 pm
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Oct 22nd, 2024 3:31 pm